Trial · NCT03285594
Adverse events240
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
121 to 140 of 240
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| serious | Reperfusion arrhythmia | Cardiac disorders | Placebo | 0 | 144 | |
| serious | Reperfusion arrhythmia | Cardiac disorders | Sotagliflozin 200 mg | 0 | 141 | |
| serious | Reperfusion arrhythmia | Cardiac disorders | Sotagliflozin 400 mg | 1 | 285 | |
| serious | Chronic obstructive pulmonary disease | Respiratory, thoracic and mediastinal disorders | Placebo | 0 | 144 | |
| serious | Chronic obstructive pulmonary disease | Respiratory, thoracic and mediastinal disorders | Sotagliflozin 200 mg | 0 | 141 | |
| serious | Chronic obstructive pulmonary disease | Respiratory, thoracic and mediastinal disorders | Sotagliflozin 400 mg | 1 | 285 | |
| serious | Pulmonary oedema | Respiratory, thoracic and mediastinal disorders | Placebo | 0 | 144 | |
| serious | Pulmonary oedema | Respiratory, thoracic and mediastinal disorders | Sotagliflozin 200 mg | 0 | 141 | |
| serious | Pulmonary oedema | Respiratory, thoracic and mediastinal disorders | Sotagliflozin 400 mg | 1 | 285 | |
| serious | Respiratory failure | Respiratory, thoracic and mediastinal disorders | Placebo | 0 | 144 | |
| serious | Respiratory failure | Respiratory, thoracic and mediastinal disorders | Sotagliflozin 200 mg | 1 | 141 | |
| serious | Respiratory failure | Respiratory, thoracic and mediastinal disorders | Sotagliflozin 400 mg | 0 | 285 | |
| serious | Sleep apnoea syndrome | Respiratory, thoracic and mediastinal disorders | Placebo | 0 | 144 | |
| serious | Sleep apnoea syndrome | Respiratory, thoracic and mediastinal disorders | Sotagliflozin 200 mg | 0 | 141 | |
| serious | Sleep apnoea syndrome | Respiratory, thoracic and mediastinal disorders | Sotagliflozin 400 mg | 1 | 285 | |
| serious | Cervicobrachial syndrome | Nervous system disorders | Placebo | 1 | 144 | |
| serious | Cervicobrachial syndrome | Nervous system disorders | Sotagliflozin 200 mg | 0 | 141 | |
| serious | Cervicobrachial syndrome | Nervous system disorders | Sotagliflozin 400 mg | 0 | 285 | |
| serious | Hypoglycaemic unconsciousness | Nervous system disorders | Placebo | 0 | 144 | |
| serious | Hypoglycaemic unconsciousness | Nervous system disorders | Sotagliflozin 200 mg | 1 | 141 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03285594/events?page=7